Previous 10 | Next 10 |
2023-03-13 23:58:45 ET Summary Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Silence Therapeutics is a de-risked investment opportunity with significant potential upside, supported by its robust pipeline, strateg...
ANI Pharmaceuticals ( NASDAQ: ANIP ) gained ~3% in the morning hours Wednesday, marking the biggest intraday gain since late January, after Guggenheim launched its coverage with a Buy recommendation citing the company’s hormonal autoimmune therapy Cortrophin Gel. Cortrophin...
Mallinckrodt plc (MNK) Q4 2022 Earnings Conference Call February 28, 2023, 8:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller and Chief Investor Relations Officer Sigurdur Olafsson - President and Chief Executive Officer Bryan Reasons - Execu...
Mallinckrodt press release ( NYSE: MNK ): Q4 Non-GAAP EPS of $4.07. Revenue of $489.3M (-18.1% Y/Y). Adjusted EBITDA was $175.5 million Fiscal 2023 Guidance: Adjusted EBITDA is $510 Million to $560 Million; Total sales of $1.70B-$1.82B For further details see: ...
Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance PR Newswire Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executi...
Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference PR Newswire DUBLIN , Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson , President ...
Mallinckrodt to Report Earnings Results for Fourth Quarter 2022 PR Newswire DUBLIN , Feb. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 ear...
---------- Company Reports Full Year 2022 Earnings of $3.73 Per Share, or $4.88 Per Share, Excluding Special Items ---------- Company Announces Reorganization and New Segmentation for 2023 ---------- Fourth Quarter Highlights: Sales of $508 Million, 6...
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today declared a regular quarterly dividend of $0.05 per share on the Company’s common stock. The dividend is payable on March 9, 2023, ...
Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress PR Newswire – Findings from a retrospective analysis suggest that patients with ba...
News, Short Squeeze, Breakout and More Instantly...
Mallinckrodt plc Company Name:
MNK Stock Symbol:
NYSE Market:
Mallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid Obligations PR Newswire Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First a...
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI,” or “the Company”) today announced that Chairman and Chief Executive Officer Douglas T. Dietrich, Chief Financial Officer Erik Aldag, and Vice President of Investor Relations Lydi...
Mallinckrodt plc Enters into Restructuring Support Agreement with Key Stakeholders on the Terms of a Prepackaged Financial Restructuring Plan PR Newswire Agreement Supported by a Substantial Majority of Each of its First and Second Lien Debtholders and Opioid Trust ...